Prenetics Global Limited (NASDAQ:PRE) Sees Significant Growth in Short Interest

by · The Cerbat Gem

Prenetics Global Limited (NASDAQ:PRE – Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 31,200 shares, an increase of 352.2% from the September 15th total of 6,900 shares. Based on an average daily trading volume, of 19,400 shares, the short-interest ratio is currently 1.6 days. Approximately 0.4% of the company’s shares are short sold.

Prenetics Global Stock Up 7.7 %

Shares of NASDAQ PRE traded up $0.30 during midday trading on Thursday, hitting $4.18. The stock had a trading volume of 7,571 shares, compared to its average volume of 58,100. The company has a market capitalization of $38.19 million, a price-to-earnings ratio of -0.94 and a beta of -0.16. Prenetics Global has a 1-year low of $2.85 and a 1-year high of $7.84. The company has a fifty day moving average price of $4.79 and a 200 day moving average price of $5.13.

Hedge Funds Weigh In On Prenetics Global

An institutional investor recently raised its position in Prenetics Global stock. Nomura Holdings Inc. lifted its position in shares of Prenetics Global Limited (NASDAQ:PRE – Free Report) by 140.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 193,963 shares of the company’s stock after acquiring an additional 113,288 shares during the period. Nomura Holdings Inc. owned about 2.12% of Prenetics Global worth $1,146,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.01% of the company’s stock.

Prenetics Global Company Profile

(Get Free Report)

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.

Read More